C R Bard (BCR) Receives Daily Media Impact Rating of 0.19

News headlines about C R Bard (NYSE:BCR) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. C R Bard earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 47.3378823373957 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the headlines that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Separately, Zacks Investment Research raised shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price on the stock in a research note on Tuesday, December 26th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. C R Bard currently has a consensus rating of “Hold” and a consensus target price of $320.83.

C R Bard stock traded down $1.95 during midday trading on Wednesday, hitting $331.24. 4,714,800 shares of the stock were exchanged, compared to its average volume of 679,456. C R Bard has a 52 week low of $222.42 and a 52 week high of $337.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37.

TRADEMARK VIOLATION NOTICE: “C R Bard (BCR) Receives Daily Media Impact Rating of 0.19” was first posted by Macon Daily and is owned by of Macon Daily. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://macondaily.com/2018/04/18/c-r-bard-bcr-receives-daily-media-impact-rating-of-0-19.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply